

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

KERYX BIOPHARMACEUTICALS INC
Form SC 13G
December 30, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Keryx Biopharmaceuticals Inc.

(Name of Issuer)

Common Stock, \$0.001 Par Value Per Share

(Title of Class of Securities)

492515101

(CUSIP Number)

December 28, 2004

(Date of Event which Requires Filing
of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

Page 1 of 13

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

S.A.C. Capital Advisors, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) []

(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

0

6 SHARED VOTING POWER

1,790,106 (includes 94,118 Shares issuable upon
exercise of warrants) (see Item 4)

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

1,790,106 (includes 94,118 Shares issuable upon
exercise of warrants) (see Item 4)

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)
(see Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7% (see Item 4)

12 TYPE OF REPORTING PERSON*

00

*SEE INSTRUCTION BEFORE FILLING OUT

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

CUSIP No. 492515101

13G

Page 3 of 13 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

S.A.C. Capital Management, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

1,790,106 (includes 94,118 Shares issuable upon
exercise of warrants) (see Item 4)

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

1,790,106 (includes 94,118 Shares issuable upon
exercise of warrants) (see Item 4)

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)
(see Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7% (see Item 4)

12 TYPE OF REPORTING PERSON*

00

*SEE INSTRUCTION BEFORE FILLING OUT

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

 CUSIP No. 492515101

13G

 Page 4 of 13 Pages

1 NAME OF REPORTING PERSON
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 S.A.C. Capital Associates, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) []
 (b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

 Anguilla, British West Indies

	5	SOLE VOTING POWER
		0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER
		920,000 (see Item 4)
	7	SOLE DISPOSITIVE POWER
		0
	8	SHARED DISPOSITIVE POWER
		920,000 (see Item 4)

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 920,000 (see Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 3.0% (see Item 4)

12 TYPE OF REPORTING PERSON*

 00

*SEE INSTRUCTION BEFORE FILLING OUT

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

 CUSIP No. 492515101

13G

 Page 5 of 13 Pages

 1 NAME OF REPORTING PERSON
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 S.A.C. Healthco Fund, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) []
 (b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

 Anguilla, British West Indies

5 SOLE VOTING POWER

 0

NUMBER OF
 SHARES
 BENEFICIALLY
 OWNED
 BY
 EACH
 REPORTING
 PERSON
 WITH

6 SHARED VOTING POWER

 814,706 (includes 94,118 Shares issuable upon
 exercise of warrants) (see Item 4)

7 SOLE DISPOSITIVE POWER

 0

8 SHARED DISPOSITIVE POWER

 814,706 (includes 94,118 Shares issuable upon
 exercise of warrants) (see Item 4)

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 814,706 (includes 94,118 Shares issuable upon exercise of warrants)
 (see Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 2.6% (see Item 4)

12 TYPE OF REPORTING PERSON*

 00

*SEE INSTRUCTION BEFORE FILLING OUT

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

Page 5 of 13

CUSIP No. 492515101

13G

Page 6 of 13 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

S.A.C. MultiQuant Fund, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Anguilla, British West Indies

5 SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

55,400 (see Item 4)

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

55,400 (see Item 4)

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

55,400 (see Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 0.1% (see Item 4)

12 TYPE OF REPORTING PERSON*

00

*SEE INSTRUCTION BEFORE FILLING OUT

IN

*SEE INSTRUCTION BEFORE FILLING OUT

Page 7 of 13

Item 1(a) Name of Issuer:

Keryx Biopharmaceuticals Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:

750 Lexington Avenue
New York, New York 10022

Items 2(a) Name of Person Filing:

This statement is filed by: (i) S.A.C. Capital Advisors, LLC, ("SAC Capital Advisors") with respect to Shares beneficially owned by S.A.C. Capital Associates, LLC ("SAC Capital Associates"), S.A.C. Healthco Fund, LLC ("SAC Healthco") and S.A.C. MultiQuant Fund, LLC ("SAC MultiQuant"); (ii) S.A.C. Capital Management, LLC, ("SAC Capital Management") with respect to Shares beneficially owned by SAC Capital Associates, SAC Healthco and SAC MultiQuant; (iii) SAC Capital Associates with respect to Shares beneficially owned by it; (iv) SAC Healthco with respect to Shares beneficially owned by it; (v) SAC MultiQuant with respect to Shares beneficially owned by it; (vi) Steven A. Cohen with respect to Shares beneficially owned by SAC Capital Advisors, SAC Capital Management, SAC Capital Associates, SAC Healthco and SAC MultiQuant.

Item 2(b) Address of Principal Business Office:

The address of the principal business office of (i) SAC Capital Advisors and Mr. Cohen is 72 Cummings Point Road, Stamford, Connecticut 06902, (ii) SAC Capital Management is 540 Madison Avenue, New York, New York 10022, and (iii) SAC Capital Associates, SAC Healthco and SAC MultiQuant is P.O. Box 58, Victoria House, The Valley, Anguilla, British West Indies.

Item 2(c) Citizenship:

SAC Capital Advisors and SAC Capital Management are Delaware limited liability companies. SAC Capital Associates, SAC Healthco and SAC MultiQuant are Anguillan limited liability companies. Mr. Cohen is a United States citizen.

Page 8 of 13

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

Item 2(d) Title of Class of Securities:

Common Stock, par value \$0.001 per share

Item 2(e) CUSIP Number:

492515101

Item 3 Not Applicable

Item 4 Ownership:

The percentages used herein are calculated based upon the Shares issued and outstanding as of November 5, 2004 as reported on the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer for the quarterly period ended September 30, 2004.

As of the close of business on December 29, 2004:

1. S.A.C. Capital Advisors, LLC
(a) Amount beneficially owned: 1,790,106
(includes 94,118 Shares issuable upon exercise of warrants)
(b) Percent of class: 5.7%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 1,790,106
(includes 94,118 Shares issuable upon exercise of warrants)
(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)

2. S.A.C. Capital Management, LLC
(a) Amount beneficially owned: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)
(b) Percent of class: 5.7%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 1,790,106
(includes 94,118 Shares issuable upon exercise of warrants)
(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)

Page 9 of 13

3. S.A.C. Capital Associates, LLC
(a) Amount beneficially owned: 920,000
(b) Percent of class: 3.0%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 920,000

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition:
920,000

4. S.A.C. Healthco Fund, LLC

(a) Amount beneficially owned: 814,706 (includes 94,118 Shares issuable upon exercise of warrants)
(b) Percent of class: 2.6%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 814,706 (includes 94,118 Shares issuable upon exercise of warrants)
(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition: 814,706 (includes 94,118 Shares issuable upon exercise of warrants)

5. S.A.C. MultiQuant Fund, LLC

(a) Amount beneficially owned: 55,400
(b) Percent of class: Less than 0.1%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 55,400
(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition: 55,400

6. Steven A. Cohen

(a) Amount beneficially owned: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)
(b) Percent of class: 5.7%
(c) (i) Sole power to vote or direct the vote: -0-
(ii) Shared power to vote or direct the vote: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)
(iii) Sole power to dispose or direct the disposition: -0-
(iv) Shared power to dispose or direct the disposition: 1,790,106 (includes 94,118 Shares issuable upon exercise of warrants)

SAC Capital Advisors, SAC Capital Management, and Mr. Cohen own directly no shares of Common Stock. Pursuant to investment agreements, each of SAC Capital Advisors and SAC Capital Management share all investment and voting power with respect to the securities held by SAC Capital Associates, SAC Healthco and SAC MultiQuant. Mr. Cohen controls each of SAC Capital Advisors and SAC Capital Management. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934,

Page 10 of 13

as amended, each of SAC Capital Advisors, SAC Capital Management and Mr. Cohen may be deemed to own beneficially 1,790,106 Shares (includes 94,118 Shares issuable upon exercise of warrants) (constituting approximately 5.7% of the Shares outstanding). Each of SAC Capital Advisors, SAC Capital Management, and Mr. Cohen disclaim beneficial ownership of any of the securities covered by this statement.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. []

Item 6 Ownership of More than Five Percent on Behalf of Another

Person:

Not Applicable

Item 7 Identification and Classification of the Subsidiary Which

Acquired the Security Being Reported on By the Parent

Holding Company:

Not Applicable

Item 8 Identification and Classification of Members

of the Group:

Not Applicable

Item 9 Notice of Dissolution of Group:

Not Applicable

Item 10 Certification:

By signing below the signatory certifies that, to the best of his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 30, 2004

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

S.A.C. CAPITAL ADVISORS, LLC

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

S.A.C. CAPITAL MANAGEMENT, LLC

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

S.A.C. CAPITAL ASSOCIATES, LLC

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

S.A.C. HEALTHCO FUND, LLC

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

Page 12 of 13

S.A.C. MULTIQUANT FUND, LLC

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

STEVEN A. COHEN

By: /s/ Peter Nussbaum

Name: Peter Nussbaum
Title: Authorized Person

Page 13 of 13